Guidant Faces More Legal Action in False Claims Lawsuit
The U.S. Department of Justice joined litigation filed by a patient, James Allen, who allegedly received one of the defective devices. Under the whistleblower or qui tam provisions of the False Claims Act, a private citizen can sue on behalf of the U.S. and share in any recovery.
In a statement, Justice officials allege that Guidant sold the Ventak Prizm 2 and the Renewal 1 and 2, even though Guidant knew the devices were defective. Despite Guidant's fixing the defect in these lines of devices, the company continued to sell their remaining stock of defective devices anyway, the government charges.
In mid-January, Guidant was fined $296 million for failing to notify the U.S. Food and Drug Administration about short-circuiting failures in three models of its implantable cardioverter defibrillators. They include the Ventak Prizm 2 DR (Model 1861) and the Contak Renewal (Models H135 and H155).
In the latest case, federal officials charge that Guidant "hid the problems with their defibrillators form patients, doctors and the FDA." In February, 2010, Guidant pleaded guilty to misleading the FDA about the problems in the devices. A district court in Minnesota accepted the company's plea on Jan. 12, 2011.
- CEO Exchange: Preparing for Population Health
- EHR Systems 'Immature, Costly,' AMA Says
- Better HCAHPS Scores Protect Revenue
- Advocate, NorthShore Deal Would Create 16-Hospital System
- Narrow Networks Cut Costs, Not Quality, Economists Say
- 3 Strategies for Retaining Millennial Employees
- Interstate Medical Licensure Effort Advances
- 'Early Offer' Malpractice Programs May Spur Reform
- Power of price: In South FL and the nation, healthcare costs often are shrouded in secrecy